Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
iBio, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'iBio, Inc. - Product Pipeline Review - 2016', provides an overview of the iBio, Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by iBio, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of iBio, Inc. - The report provides overview of iBio, Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses iBio, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features iBio, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate iBio, Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for iBio, Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding iBio, Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 iBio, Inc. Snapshot 6 iBio, Inc. Overview 6 Key Information 6 Key Facts 6 iBio, Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 iBio, Inc. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 iBio, Inc. - Pipeline Products Glance 13 iBio, Inc. - Clinical Stage Pipeline Products 13 Phase I Products/Combination Treatment Modalities 13 iBio, Inc. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 iBio, Inc. - Drug Profiles 16 anthrax vaccine 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 HAI-05 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 influenza [strain A/H1N1] vaccine 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 malaria vaccine 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 NaAPR1M-74 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 anthrax + plague vaccine 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 human papillomavirus [Serotype 16] vaccine 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 IBIOCFB-03 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Monoclonal Antibody for Anthrax 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Monoclonal Antibody to Inhibit Neuraminidase for Influenza 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 palivizumab biosimilar 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 yellow fever vaccine 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 influenza [strain A/H7N9] vaccine 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Recombinant Protein for Oncology 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 trypanosomiasis vaccine 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 iBio, Inc. - Pipeline Analysis 35 iBio, Inc. - Pipeline Products by Target 35 iBio, Inc. - Pipeline Products by Route of Administration 36 iBio, Inc. - Pipeline Products by Molecule Type 37 iBio, Inc. - Pipeline Products by Mechanism of Action 38 iBio, Inc. - Recent Pipeline Updates 39 iBio, Inc. - Dormant Projects 44 iBio, Inc. - Locations And Subsidiaries 45 Head Office 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 46 Disclaimer 47
List of Tables
iBio, Inc., Key Information 6 iBio, Inc., Key Facts 6 iBio, Inc. - Pipeline by Indication, 2016 9 iBio, Inc. - Pipeline by Stage of Development, 2016 10 iBio, Inc. - Monotherapy Products in Pipeline, 2016 11 iBio, Inc. - Combination Treatment Modalities in Pipeline, 2016 12 iBio, Inc. - Phase I, 2016 13 iBio, Inc. - Preclinical, 2016 14 iBio, Inc. - Discovery, 2016 15 iBio, Inc. - Pipeline by Target, 2016 35 iBio, Inc. - Pipeline by Route of Administration, 2016 36 iBio, Inc. - Pipeline by Molecule Type, 2016 37 iBio, Inc. - Pipeline Products by Mechanism of Action, 2016 38 iBio, Inc. - Recent Pipeline Updates, 2016 39 iBio, Inc. - Dormant Developmental Projects,2016 44
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
